JP Morgan Chase’s Cellectis CLLS Stock Holding History

JP Morgan Chase’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-30,000	Closed	-$849K	–	5677
2018 Q2	$849K	Buy	+30,000	New	+$893K	﹤0.01%	3919
2018 Q1	–	Sell	-40,000	Closed	-$1.17M	–	5407
2017 Q4	$1.17M	Buy	+40,000	New	+$1.09M	﹤0.01%	3639

Other funds holding CLLS

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JP Morgan Chase's CLLS Position: Q4 2025 in Review

JP Morgan Chase sold out of Cellectis (CLLS) in Q4 2025, closing a stake of 4,945 shares — an estimated $14.1K sold.

JP Morgan Chase first reported a position in CLLS in Q1 2015 and held it in 37 quarters. The position peaked at $10.8M in Q2 2015. 34 funds tracked by Wall St. Rank hold CLLS as of Q4 2025.

JP Morgan Chase reported no remaining Cellectis position as of Q4 2025 after selling out during the quarter.
JP Morgan Chase sold 4,945 Cellectis shares in Q4 2025, an estimated $14.1K.
JP Morgan Chase first reported a position in Cellectis in Q1 2015 and held it in 37 quarters.
JP Morgan Chase's Cellectis position peaked at $10.8M in Q2 2015.
34 funds tracked by Wall St. Rank held Cellectis as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.